Electrophysiologic correlations with clinical outcomes in CIDP

Muscle and Nerve

Volumn 42, Issue 4, 2010, Pages 492-497

  Bril, Vera ^a   Banach, Marta ^b   Dalakas, Marinos C ^c   Deng, Chunqin ^d   Donofrio, Peter ^e   Hanna, Kim ^d   Hartung, Hans Peter ^f   Hughes, Richard A C ^g   Katzberg, Hans ^h   Latov, Norman ⁱ   Merkies, Ingemar S J ^j   Van Doorn, Pieter A ^j  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Talecris Biotherapeutics Inc   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^h STANFORD UNIVERSITY   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chronic inflammatory demyelinating; Clinical trial; Peripheral nervous system diseases; Polyneuropathies; Polyradiculoneuropathy

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; OCTANOIC ACID; PLACEBO; OCTANOIC ACID DERIVATIVE;

ADULT; ARTICLE; CHROMATOGRAPHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; GRIP STRENGTH; HAND GRIP; HUMAN; MAJOR CLINICAL STUDY; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ACTION POTENTIAL; AGED; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; MIDDLE AGED; MOTONEURON; NERVE CONDUCTION; PATHOPHYSIOLOGY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIAL;

ACTION POTENTIALS; ADULT; AGED; CAPRYLATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROPHYSIOLOGICAL PHENOMENA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; MOTOR NEURONS; NEURAL CONDUCTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME;

EID: 77957663149     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21733     Document Type: Article

References (14)

1. Chan Y-C, Wilder-Smith E. Predicting treatment response in chronic, acquired demyelinating neuropathies. Expert Rev Neurother 2006;6: 1545-1553. (Pubitemid 44690922)
2. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
3. [No authors listed.] Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617-618.
4. Boukhris S, Magy L, Kabore R, Mabrouk T, Li Y, Sindou P, et al. Atypical electrophysiologic findings in chronic inflammatory demyelinating polyneuropathy (CIDP) - diagnosis confirmed by nerve biopsy. Neurophysiol Clin 2004;34:71-79. (Pubitemid 38586794)
5. Chan Y-C, Allen DC, Fialho D, Mills KR, Hughes RA. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2006;77:114-116. (Pubitemid 43022709)
6. Hughes RAC, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al, on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7: 136-144.
7. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838-845.
8. Kuwabara S, Ogawara K, Misawa S, Mori M, Hattori T. Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002;72:37-42. (Pubitemid 34073093)
9. Bril V, Katzberg H, Donofrio P, Banach M, Dalakas MC, Deng C, et al, on behalf of the ICE Study Group. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009;39:448-455.
10. Ashworth NL, Zochodne DW, Hahn AF, Pillay N, Chalk C, Benstead T, et al. Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2000;23:206-210.
11. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
12. Merkies ISJ, Schmitz PIM, Samijn JPA, Meché FG, Toyka KV, van Doorn PA, for the Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 2000;23:1393-1401.
13. Merkies ISJ, Schmitz PIM, van der Meché FGA, Samijn JP, van Doorn PA, for the Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.
14. Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung H-P, et al. Electrophysiologic correlations to clinical outcomes in chronic inflammatory demyelinating polyneuropathy (CIDP). Poster presented at the 133rd Annual Meeting of the American Neurological Association; September 21-24, 2008; Salt Lake City, UT, USA.